Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from May 27, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 25, 2026 — +10.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$42.17 – $44.07Entry zone — fair-value band

$44.13Published — price the day we called it

$47.50Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$48.66Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 35 days.

At window close

+10.3%

realized, from the publication price to the last close inside the window

Peak gain

+16.6%

peak, from the publication price — not a realized return

S&P 500, same window

+2.3%

SPY over the identical days, dividend-adjusted

Window close

$48.66

last close inside the window, ended August 25, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published May 27, 2026

Predicted growth

+9%

over the measurement window

Target price

$47.50

the price the thesis aimed for

Entry zone

$42.17 – $44.07

the fair-value band we waited for

Price at publication

$44.13

published May 27, 2026

Confidence

81%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk combines steady growth with strong profits and a lower valuation than some peers. New clinical news around CagriSema, zenagamtide and cardiometabolic data could spark short-term interest. A recent earnings miss and higher debt reduce conviction, but oversold price action and better sentiment make a rebound in the next 0-3 months plausible.

Primary drivers

Clinical presentations can renew interest in cardiometabolic growth
Leading GLP-1 position supports steady demand in diabetes and obesity
Lower valuation offers some downside protection versus richer peers
Oversold price action can enable a tactical rebound if support holds

How it played out

NVO: target reached in 35 days

Lyra published a short-term rebound thesis at $44.13, with expected growth of 9% and a $47.50 target. The thesis pointed to clinical presentations for CagriSema, zenagamtide and cardiometabolic data, steady demand in diabetes and obesity, a lower valuation, and oversold price action. A recent earnings miss and higher debt reduced conviction.

NVO reached the target in 35 days. It later peaked at $51.46 on July 29, a gain of 16.6%. The shares ended the window at $48.66, still above the target. The thesis played out and exceeded its stated price objective.

What happened during the window

On June 6, Novo Nordisk reported positive phase 2 zenagamtide data and said the treatment would advance into phase 3 trials. On August 4, the company reported adjusted operating profit of DKK 33,389 million for the second quarter and raised its full-year outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals